Innova Biosciences has announced that it has been awarded a development of prototype grant circa £210,000 by the Technology Strategy Board, with matched company funding of approximately £250,000, to develop novel nanoparticle products for diagnostics applications.
The growing diagnostic market requires nanoparticles that have been linked to antibodies, but the methods for creating these hybrid reagents are complex.
The Technology Strategy Board grant, awarded through its Smart programme, will allow Innova to develop high quality reagents using much simpler linking technologies.
The use of nanoparticles in life sciences, including diagnostics, is a high value sector and the award of the grant will extend Innova’s penetration into this industry.
Nick Gee (CEO of Innova Biosciences) comments ‘The award of the grant in such a competitive environment underlines Innova’s excellent track record and its on-going commitment to innovation. We expect that the products and technologies emerging from this new programme will transform the way in which nanoparticle reagents are created in the future.’